Effects of sustained-release trimetazidine on chronically dysfunctional myocardium of ischemic dilated cardiomyopathy – Six months follow-up result

BACKGROUND: Ischemic cardiomyopathy is a growing burden in third world countries. So far, benefits of trimetazidine in this group of patients have been suggested by clinical trials mainly conducted in Europe. We evaluated the effect of trimetazidine on ischemic dilated cardiomyopathy in our populati...

Descripción completa

Detalles Bibliográficos
Autores principales: Momen, A., Ali, M., Karmakar, P.K., Ali, M.Z., Haque, A., Khan, M.R., Khalil, M.I., Hossain, M.S., Huda, R.M., Goni, M.N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143824/
https://www.ncbi.nlm.nih.gov/pubmed/27931552
http://dx.doi.org/10.1016/j.ihj.2016.03.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143824/
https://www.ncbi.nlm.nih.gov/pubmed/27931552
http://dx.doi.org/10.1016/j.ihj.2016.03.021

Ejemplares similares